These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 15971432)
1. Successful treatment of osteolytic epithelioid hemangioendothelioma with pamidronate. Coppo P; Lassoued S; Billey T; Lassoued K Clin Exp Rheumatol; 2005; 23(3):400-1. PubMed ID: 15971432 [TBL] [Abstract][Full Text] [Related]
2. Procollagen type I N-propeptide is a predictor of skeletal morbidity in patients with malignant osteolytic bone disease on bisphosphonates. Joerger M; Templeton A; Köberle D; Engler H; Riesen WF; Thürlimann B Cancer Chemother Pharmacol; 2011 May; 67(5):1137-44. PubMed ID: 20683595 [TBL] [Abstract][Full Text] [Related]
3. The multicentric epitheloid hemangioendothelioma of bone: a case example and review of the literature. Gosheger G; Hardes J; Ozaki T; Horst E; Bürger H; Winkelmann W J Cancer Res Clin Oncol; 2002 Jan; 128(1):11-8. PubMed ID: 11862467 [TBL] [Abstract][Full Text] [Related]
4. Use of image processing techniques to assess effect of disodium pamidronate in conjunction with radiotherapy in patients with bone metastases. Kouloulias VE; Dardoufas CE; Kouvaris JR; Antypas CE; Sandilos PH; Matsopoulos GK; Vlahos LJ Acta Oncol; 2002; 41(2):169-74. PubMed ID: 12102162 [TBL] [Abstract][Full Text] [Related]
5. An intra-patient dose-escalation study of disodium pamidronate plus radiotherapy versus radiotherapy alone for the treatment of osteolytic metastases. Monitoring of recalcification using image-processing techniques. Kouloulias EV; Kouvaris RJ; Antypas C; Mystakidou K; Matsopoulos G; Uzunoglu CN; Moulopoulos A; Vlahos JL Strahlenther Onkol; 2003 Jul; 179(7):471-9. PubMed ID: 12835884 [TBL] [Abstract][Full Text] [Related]
6. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience). Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777 [TBL] [Abstract][Full Text] [Related]
7. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Rosen LS; Gordon DH; Dugan W; Major P; Eisenberg PD; Provencher L; Kaminski M; Simeone J; Seaman J; Chen BL; Coleman RE Cancer; 2004 Jan; 100(1):36-43. PubMed ID: 14692022 [TBL] [Abstract][Full Text] [Related]
8. Fitting new modalities into practice guidelines. Theriault RL Oncology (Williston Park); 1997 Nov; 11(11A):145-9. PubMed ID: 9430184 [TBL] [Abstract][Full Text] [Related]
9. Antiresorptive Therapies for the Treatment of Malignant Osteolytic Bone Disease. Mehrotra B Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):561-6. PubMed ID: 26515737 [TBL] [Abstract][Full Text] [Related]
10. Locally administered zoledronic Acid therapy for giant cell tumor of bone. Nishisho T; Hanaoka N; Endo K; Takahashi M; Yasui N Orthopedics; 2011 Jul; 34(7):e312-5. PubMed ID: 21717996 [TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates in the treatment of malignant bone disease. Berenson JR; Lipton A Annu Rev Med; 1999; 50():237-48. PubMed ID: 10073275 [TBL] [Abstract][Full Text] [Related]
12. Hemangioendothelioma of the sphenoid bone: a case report. Joo M; Lee GJ; Koh YC; Park YK J Korean Med Sci; 2001 Apr; 16(2):241-4. PubMed ID: 11306756 [TBL] [Abstract][Full Text] [Related]
13. Malignant epithelioid hemangioendothelioma at the site of a hip prosthesis. van der List JJ; van Horn JR; Slooff TJ; ten Cate LN Acta Orthop Scand; 1988 Jun; 59(3):328-30. PubMed ID: 3381668 [TBL] [Abstract][Full Text] [Related]
14. Hemangioendothelioma of bone. A report of an unusual case with lymph node metastasis. Volpe R; Carbone A; Manconi R; Santi L Pathol Res Pract; 1985 Nov; 180(5):521-5. PubMed ID: 4080637 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. Hortobagyi GN; Theriault RL; Porter L; Blayney D; Lipton A; Sinoff C; Wheeler H; Simeone JF; Seaman J; Knight RD N Engl J Med; 1996 Dec; 335(24):1785-91. PubMed ID: 8965890 [TBL] [Abstract][Full Text] [Related]
16. [Malignant hemangioendothelioma of bone. Report of a case]. Cayla J; Roger M; Rondier J; Guiraudon C; Malherbe M; Grellet J Rev Rhum Mal Osteoartic; 1977 May; 44(5):354-8. PubMed ID: 887898 [No Abstract] [Full Text] [Related]
17. Progress in the treatment and palliation of advanced breast cancer: does the dose of pamidronate determine its effects? Thürlimann B Ann Oncol; 1994; 5 Suppl 7():S45-7. PubMed ID: 7532993 [TBL] [Abstract][Full Text] [Related]
19. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein M; Coleman RE; Reitsma DJ; Seaman JJ; Chen BL; Ambros Y Cancer J; 2001; 7(5):377-87. PubMed ID: 11693896 [TBL] [Abstract][Full Text] [Related]
20. Palliative treatment of painful bone metastases from non-Hodgkin lymphoma with disodium pamidronate. Pistevou-Gombaki K; Eleftheriadis N; Sofroniadis I; Makris P; Kouloulias V J Exp Clin Cancer Res; 2002 Sep; 21(3):429-32. PubMed ID: 12385590 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]